The Critical Role of Adjuvants in Modern Vaccinology
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Design, Development, and Delivery".
Deadline for manuscript submissions: 15 August 2026 | Viewed by 6
Special Issue Editor
Interests: vaccine delivery technology; novel vaccines and adjuvants
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
There is a lack of safe and effective adjuvants to support the development of new and improved vaccines. Often, different types of adjuvants are necessary to induce optimal immune responses for specific diseases, and adjuvants may need to be tailored to specific age groups. Historically, the development of adjuvants has relied mainly on empirical experience, with only a handful of adjuvants approved for human use since the first, Alum, was discovered over 90 years ago. However, substantial advances have been made over the last three decades in our understanding of how adjuvants function.
This Special Issue will include commentaries, original research articles, and reviews related to the discovery and development of adjuvants for various types of vaccines, such as subunit and mRNA-based vaccines to combat infectious diseases, cancer, and immune-mediated diseases. Additionally, we welcome studies on the mechanisms of adjuvants and investigations into the development of combinatorial adjuvants for vaccine applications.
Dr. Xinyuan Chen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine adjuvant
- mechanism
- combinatorial adjuvant
- subunit
- mRNA
- vaccine discovery
- vaccine development
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
